Ladiratuzumab vedotin
- Generic Name
- Ladiratuzumab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1629760-29-7
- Unique Ingredient Identifier
- VM4G5D1A60
- Background
Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
- Associated Conditions
- -
- Associated Therapies
- -
Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT06362590
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT04032704
- Locations
- 🇺🇸
FirstHealth of the Carolinas, Pinehurst, North Carolina, United States
🇺🇸Adventist Health White Memorial, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT03310957
- Locations
- 🇩🇪
Marien Hospital Bottrop, Bottrop, Other, Germany
🇩🇪Klinikum der Universitat Munchen, Munchen, Other, Germany
🇰🇷Samsung Medical Center, Seoul, Other, Korea, Republic of
A Safety Study of SGN-LIV1A in Breast Cancer Patients
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT01969643
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Northwest Medical Specialties, Puyallup, Washington, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Conditions
- Interventions
- Drug: Standard TherapyDrug: AMG 386 with or without TrastuzumabDrug: AMG 479 (Ganitumab) plus MetforminDrug: MK-2206 with or without TrastuzumabDrug: T-DM1 and PertuzumabDrug: Pertuzumab and TrastuzumabDrug: GanetespibDrug: ABT-888Drug: NeratinibDrug: PLX3397Drug: Pembrolizumab - 4 cycleDrug: Talazoparib plus IrinotecanDrug: Patritumab and TrastuzumabDrug: Pembrolizumab - 8 cycleDrug: SGN-LIV1ADrug: Durvalumab plus OlaparibDrug: SD-101 + PembrolizumabDrug: Tucatinib plus trastuzumab and pertuzumabDrug: CemiplimabDrug: Cemiplimab plus REGN3767Drug: Trilaciclib with or without trastuzumab + pertuzumabDrug: SYD985 ([vic-]trastuzumab duocarmazine)Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug: Dan222 + NiraparibDrug: Sarilumab + Cemiplimab + PaclitaxelDrug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug: AmcenestrantDrug: Amcenestrant + AbemaciclibDrug: Amcenestrant + LetrozoleDrug: ARX788Drug: ARX788 + CemiplimabDrug: VV1 + CemiplimabDrug: Datopotamab deruxtecanDrug: Datopotamab deruxtecan + DurvalumabDrug: ZanidatamabDrug: LasofoxifeneDrug: Z-endoxifenDrug: ARV-471Drug: ARV-471 + LetrozoleDrug: ARV-471 + AbemaciclibDrug: Endoxifen + AbemaciclibDrug: Rilvegostomig + TDXdDrug: AMG 386 and Trastuzumab
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 5000
- Registration Number
- NCT01042379
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Kansas, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.